Adjuvant endocrine therapy side-effects among postmenopausal breast cancer patients in Malaysia

S. B. Choo, A. Saifulbahri, S. N. Zullkifli, M. L. Fadzil, Adyani Md Redzuan, N. Abdullah, R. S.Ahmad Bustamam, H. Z. Ahmad, Noraida Mohamed Shah

Research output: Contribution to journalArticle

Abstract

Objective: This study was conducted to determine the prevalence and severity of menopausal symptoms and their associated risk factors among postmenopausal breast cancer patients receiving adjuvant endocrine therapy. Methods: Postmenopausal breast cancer patients on endocrine therapy were recruited at three hospitals in Malaysia. Presence and severity of menopausal symptoms were determined using the Menopause Rating Scale. Sociodemographic and clinical data were collected from medical records. Results: A total of 192 patients participated in this study. Commonly reported symptoms were musculoskeletal pain (59.9%), physical and mental exhaustion (59.4%), and hot flushes (41.1%). Multivariate analyses indicated that increasing number of years after menopause until the start of endocrine therapy was significantly associated with less likelihood of reporting menopausal symptoms and musculoskeletal pain. Patients with primary or secondary education levels reported significantly less menopausal urogenital symptoms compared to patients with a tertiary education level. Patients using aromatase inhibitors were twice as likely to experience musculoskeletal pain compared to patients using tamoxifen (odds ratio, 2.18; 95% confidence interval, 1.06–4.50; p < 0.05). Conclusion: Menopausal symptoms and musculoskeletal pain are common problems encountered by postmenopausal breast cancer patients receiving adjuvant endocrine therapy and should be closely monitored for successful treatment.

Original languageEnglish
JournalClimacteric
DOIs
Publication statusAccepted/In press - 1 Jan 2018

Fingerprint

Malaysia
Breast Neoplasms
Musculoskeletal Pain
Therapeutics
Menopause
Education
Aromatase Inhibitors
Tamoxifen
Medical Records
Multivariate Analysis
Odds Ratio
Confidence Intervals

Keywords

  • Adjuvant endocrine therapy
  • breast cancer
  • Malaysia
  • postmenopausal

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Adjuvant endocrine therapy side-effects among postmenopausal breast cancer patients in Malaysia. / Choo, S. B.; Saifulbahri, A.; Zullkifli, S. N.; Fadzil, M. L.; Md Redzuan, Adyani; Abdullah, N.; Bustamam, R. S.Ahmad; Ahmad, H. Z.; Mohamed Shah, Noraida.

In: Climacteric, 01.01.2018.

Research output: Contribution to journalArticle

Choo, S. B. ; Saifulbahri, A. ; Zullkifli, S. N. ; Fadzil, M. L. ; Md Redzuan, Adyani ; Abdullah, N. ; Bustamam, R. S.Ahmad ; Ahmad, H. Z. ; Mohamed Shah, Noraida. / Adjuvant endocrine therapy side-effects among postmenopausal breast cancer patients in Malaysia. In: Climacteric. 2018.
@article{63d0b7ac8399497db9aae7a76ba80c0c,
title = "Adjuvant endocrine therapy side-effects among postmenopausal breast cancer patients in Malaysia",
abstract = "Objective: This study was conducted to determine the prevalence and severity of menopausal symptoms and their associated risk factors among postmenopausal breast cancer patients receiving adjuvant endocrine therapy. Methods: Postmenopausal breast cancer patients on endocrine therapy were recruited at three hospitals in Malaysia. Presence and severity of menopausal symptoms were determined using the Menopause Rating Scale. Sociodemographic and clinical data were collected from medical records. Results: A total of 192 patients participated in this study. Commonly reported symptoms were musculoskeletal pain (59.9{\%}), physical and mental exhaustion (59.4{\%}), and hot flushes (41.1{\%}). Multivariate analyses indicated that increasing number of years after menopause until the start of endocrine therapy was significantly associated with less likelihood of reporting menopausal symptoms and musculoskeletal pain. Patients with primary or secondary education levels reported significantly less menopausal urogenital symptoms compared to patients with a tertiary education level. Patients using aromatase inhibitors were twice as likely to experience musculoskeletal pain compared to patients using tamoxifen (odds ratio, 2.18; 95{\%} confidence interval, 1.06–4.50; p < 0.05). Conclusion: Menopausal symptoms and musculoskeletal pain are common problems encountered by postmenopausal breast cancer patients receiving adjuvant endocrine therapy and should be closely monitored for successful treatment.",
keywords = "Adjuvant endocrine therapy, breast cancer, Malaysia, postmenopausal",
author = "Choo, {S. B.} and A. Saifulbahri and Zullkifli, {S. N.} and Fadzil, {M. L.} and {Md Redzuan}, Adyani and N. Abdullah and Bustamam, {R. S.Ahmad} and Ahmad, {H. Z.} and {Mohamed Shah}, Noraida",
year = "2018",
month = "1",
day = "1",
doi = "10.1080/13697137.2018.1540563",
language = "English",
journal = "Climacteric",
issn = "1369-7137",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Adjuvant endocrine therapy side-effects among postmenopausal breast cancer patients in Malaysia

AU - Choo, S. B.

AU - Saifulbahri, A.

AU - Zullkifli, S. N.

AU - Fadzil, M. L.

AU - Md Redzuan, Adyani

AU - Abdullah, N.

AU - Bustamam, R. S.Ahmad

AU - Ahmad, H. Z.

AU - Mohamed Shah, Noraida

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: This study was conducted to determine the prevalence and severity of menopausal symptoms and their associated risk factors among postmenopausal breast cancer patients receiving adjuvant endocrine therapy. Methods: Postmenopausal breast cancer patients on endocrine therapy were recruited at three hospitals in Malaysia. Presence and severity of menopausal symptoms were determined using the Menopause Rating Scale. Sociodemographic and clinical data were collected from medical records. Results: A total of 192 patients participated in this study. Commonly reported symptoms were musculoskeletal pain (59.9%), physical and mental exhaustion (59.4%), and hot flushes (41.1%). Multivariate analyses indicated that increasing number of years after menopause until the start of endocrine therapy was significantly associated with less likelihood of reporting menopausal symptoms and musculoskeletal pain. Patients with primary or secondary education levels reported significantly less menopausal urogenital symptoms compared to patients with a tertiary education level. Patients using aromatase inhibitors were twice as likely to experience musculoskeletal pain compared to patients using tamoxifen (odds ratio, 2.18; 95% confidence interval, 1.06–4.50; p < 0.05). Conclusion: Menopausal symptoms and musculoskeletal pain are common problems encountered by postmenopausal breast cancer patients receiving adjuvant endocrine therapy and should be closely monitored for successful treatment.

AB - Objective: This study was conducted to determine the prevalence and severity of menopausal symptoms and their associated risk factors among postmenopausal breast cancer patients receiving adjuvant endocrine therapy. Methods: Postmenopausal breast cancer patients on endocrine therapy were recruited at three hospitals in Malaysia. Presence and severity of menopausal symptoms were determined using the Menopause Rating Scale. Sociodemographic and clinical data were collected from medical records. Results: A total of 192 patients participated in this study. Commonly reported symptoms were musculoskeletal pain (59.9%), physical and mental exhaustion (59.4%), and hot flushes (41.1%). Multivariate analyses indicated that increasing number of years after menopause until the start of endocrine therapy was significantly associated with less likelihood of reporting menopausal symptoms and musculoskeletal pain. Patients with primary or secondary education levels reported significantly less menopausal urogenital symptoms compared to patients with a tertiary education level. Patients using aromatase inhibitors were twice as likely to experience musculoskeletal pain compared to patients using tamoxifen (odds ratio, 2.18; 95% confidence interval, 1.06–4.50; p < 0.05). Conclusion: Menopausal symptoms and musculoskeletal pain are common problems encountered by postmenopausal breast cancer patients receiving adjuvant endocrine therapy and should be closely monitored for successful treatment.

KW - Adjuvant endocrine therapy

KW - breast cancer

KW - Malaysia

KW - postmenopausal

UR - http://www.scopus.com/inward/record.url?scp=85058675153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85058675153&partnerID=8YFLogxK

U2 - 10.1080/13697137.2018.1540563

DO - 10.1080/13697137.2018.1540563

M3 - Article

C2 - 30556740

AN - SCOPUS:85058675153

JO - Climacteric

JF - Climacteric

SN - 1369-7137

ER -